Aging
Navigate
Submit an Article
Research Paper|Volume 10, Issue 5|pp 973—987

Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma

Cheng-Cao Sun1,2, Qun Zhou3, Wei Hu3, Shu-Jun Li4, Feng Zhang3, Zhen-Long Chen4, Guang Li5, Zhuo-Yue Bi6, Yong-Yi Bi3, Feng-Yun Gong7, Tao Bo7, Zhan-Peng Yuan3, Wei-Dong Hu8, Bo-Tao Zhan9, Qian Zhang10, Qi-Zhu Tang11, De-Jia Li3
  • 1Department of Preventive Medicine, School of Health Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China
  • 2Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • 3Department of Occupational and Environmental Health, School of Health Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China
  • 4Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, Wuhan, Hubei 430022, P.R. China
  • 5Department of Oncology, Wuhan Pu-Ai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430034, P.R. China
  • 6Hubei Provincial Key Laboratory for Applied Toxicology (Hubei Provincial Academy for Preventive Medicine), Wuhan, Hubei 430079, P.R. China
  • 7Department of Infectious Diseases, Wuhan Medical Treatment Center, Wuhan, Hubei 430023, P.R. China
  • 8Department of Oncology, ZhongNan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
  • 9Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 430021, P.R. China
  • 10Department of Pathology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
  • 11Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China

* * Equal contribution

Received: March 22, 2018Accepted: April 28, 2018Published: May 11, 2018
https://doi.org/10.18632/aging.101441

Copyright: © 2018 Sun et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

E2F is a group of genes that encode a family of transcription factors (TFs) in higher eukaryotes and participate in cell cycle regulation and DNA synthesis in mammalian cells. Evidence from cell lines, mouse models, and human tissues indicates that TFs are implicated in lung cancer (LC) tumorigenesis. However, the diverse expression patterns and prognostic values of eight E2Fs have yet to be elucidated. In the current study, we examined the transcriptional and survival data of E2Fs in patients with LC from ONCOMINE, GEPIA, Kaplan–Meier Plotter, and cBioPortal databases. We found that the expression levels of E2F1/2/3/5/6/7/8 were higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in lung tissues, whereas the expression level of E2F4 was lower in the former than in the latter. The expression levels of E2F2/4/5/7/8 were correlated with advanced tumor stage. Survival analysis using the Kaplan–Meier Plotter database revealed that the high transcription levels of E2F1/2/4/5/7/8 were associated with low relapse-free survival (RFS) in all of the patients with LC. Conversely, high E2F3/6 levels predicted high RFS in these patients. This study implied that E2F3/6/7 are potential targets of precision therapy for patients with LC and that E2F1/2/4/5/8 are new biomarkers for the prognosis of LC.